Mayfair Advisory Group LLC Boosts Stake in Amgen Inc. $AMGN

Mayfair Advisory Group LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 33.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,098 shares of the medical research company’s stock after acquiring an additional 275 shares during the period. Mayfair Advisory Group LLC’s holdings in Amgen were worth $316,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of AMGN. Elevation Point Wealth Partners LLC increased its position in shares of Amgen by 15.2% in the second quarter. Elevation Point Wealth Partners LLC now owns 857 shares of the medical research company’s stock worth $239,000 after purchasing an additional 113 shares during the last quarter. GM Advisory Group LLC grew its stake in Amgen by 115.1% in the 2nd quarter. GM Advisory Group LLC now owns 2,657 shares of the medical research company’s stock worth $742,000 after buying an additional 1,422 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Amgen by 11.6% in the 2nd quarter. Quadrant Capital Group LLC now owns 15,133 shares of the medical research company’s stock worth $4,225,000 after buying an additional 1,569 shares during the last quarter. Vinva Investment Management Ltd increased its stake in Amgen by 33.0% in the second quarter. Vinva Investment Management Ltd now owns 36,950 shares of the medical research company’s stock valued at $10,240,000 after acquiring an additional 9,178 shares during the last quarter. Finally, Wambolt & Associates LLC bought a new position in Amgen in the second quarter valued at $236,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 10,908 shares of company stock valued at $3,674,966. Company insiders own 0.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on AMGN shares. Deutsche Bank Aktiengesellschaft lifted their price target on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research note on Tuesday, November 11th. Citigroup raised their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Daiwa Capital Markets lifted their price target on shares of Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Finally, DZ Bank upped their price objective on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $333.74.

Amgen Trading Up 1.0%

Shares of AMGN opened at $344.57 on Thursday. The firm has a fifty day simple moving average of $304.95 and a two-hundred day simple moving average of $293.90. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $345.84. The stock has a market capitalization of $185.54 billion, a P/E ratio of 28.17, a PEG ratio of 2.61 and a beta of 0.45. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period last year, the firm earned $5.58 earnings per share. Amgen’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be issued a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a yield of 2.8%. Amgen’s dividend payout ratio is 73.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.